Danaher (NYSE:DHR) Stock Acquired Rep. Robert Bresnahan, Jr.

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of Danaher Co. NYSE: DHR. In a filing disclosed on May 08th, the Representative disclosed that they had bought between $15,001 and $50,000 in Danaher stock on April 8th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 4/17/2025.
• Sold $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 4/16/2025.
• Sold $1,001 - $15,000 in shares of Western Digital NASDAQ: WDC on 4/11/2025.
• Sold $1,001 - $15,000 in shares of Western Digital NASDAQ: WDC on 4/10/2025.
• Sold $1,001 - $15,000 in shares of DexCom NASDAQ: DXCM on 4/8/2025.
• Sold $1,001 - $15,000 in shares of Invesco NYSE: IVZ on 4/8/2025.
• Sold $1,001 - $15,000 in shares of Generac NYSE: GNRC on 4/8/2025.
• Sold $15,001 - $50,000 in shares of Occidental Petroleum NYSE: OXY on 4/8/2025.
• Sold $15,001 - $50,000 in shares of Pfizer NYSE: PFE on 4/8/2025.
• Sold $1,001 - $15,000 in shares of QUALCOMM NASDAQ: QCOM on 4/8/2025.

Danaher Price Performance

NYSE:DHR traded down $5.40 during mid-day trading on Friday, hitting $189.42. 4,535,806 shares of the stock traded hands, compared to its average volume of 3,403,646. The business's 50-day moving average price is $198.39 and its 200 day moving average price is $219.46. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The company has a market cap of $135.56 billion, a PE ratio of 35.88, a price-to-earnings-growth ratio of 2.66 and a beta of 0.80. Danaher Co. has a 12-month low of $171.00 and a 12-month high of $281.70.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, beating analysts' consensus estimates of $1.62 by $0.26. The business had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.58 billion. Danaher had a return on equity of 10.82% and a net margin of 16.33%. On average, analysts expect that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.68%. Danaher's payout ratio is presently 24.85%.

Hedge Funds Weigh In On Danaher

Several large investors have recently modified their holdings of the stock. GHP Investment Advisors Inc. raised its holdings in Danaher by 396.0% in the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock worth $25,000 after acquiring an additional 99 shares during the last quarter. Heck Capital Advisors LLC bought a new stake in Danaher in the 4th quarter worth about $27,000. Sierra Ocean LLC lifted its stake in Danaher by 116.9% during the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock valued at $29,000 after acquiring an additional 76 shares during the period. Decker Retirement Planning Inc. purchased a new stake in shares of Danaher during the 4th quarter valued at about $31,000. Finally, Golden State Wealth Management LLC bought a new stake in shares of Danaher in the fourth quarter worth approximately $31,000. Hedge funds and other institutional investors own 79.05% of the company's stock.

Wall Street Analysts Forecast Growth

DHR has been the topic of several analyst reports. Barclays lifted their price objective on Danaher from $205.00 to $215.00 and gave the stock an "overweight" rating in a report on Tuesday, April 22nd. Raymond James reiterated a "market perform" rating on shares of Danaher in a research report on Monday, February 3rd. Citigroup restated a "buy" rating on shares of Danaher in a report on Monday, April 7th. Jefferies Financial Group lowered their price target on shares of Danaher from $260.00 to $230.00 and set a "buy" rating for the company in a report on Tuesday, April 22nd. Finally, The Goldman Sachs Group cut their price target on shares of Danaher from $260.00 to $240.00 and set a "neutral" rating on the stock in a report on Wednesday, April 23rd. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, Danaher presently has an average rating of "Moderate Buy" and an average target price of $264.40.

Insider Activity at Danaher

In other news, EVP Christopher Paul Riley sold 15,805 shares of the company's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the sale, the executive vice president now owns 15,179 shares of the company's stock, valued at $3,005,442. This represents a 51.01 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 11.10% of the stock is owned by insiders.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.